Skip to main content
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · MIRM ISIN · US6047491013 LEI · 254900YZKR40F7F27K81 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US MIRM

About Mirum Pharmaceuticals, Inc.

https://mirumpharma.com/

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a primary focus on debilitating liver conditions affecting both children and adults. The company's lead commercial product is LIVMARLI® (maralixibat), an oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome. Mirum's clinical pipeline is advancing other potential treatments, including volixibat, for various rare cholestatic liver diseases. The company's mission is to transform the treatment landscape for patients with significant unmet medical needs by advancing its scientific programs from discovery through commercialization.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-18 English
10-Q - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-06 English
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Regulatory Filings
2026-05-04 English
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The content describes the announcement of clinical trial results (Phase 2b portion of the AZURE-1 study) for Mirum Pharmaceuticals, including efficacy and safety data. It does not contain comprehensive financial statements or detailed management discussion typical of annual or quarterly reports. It is not a transcript, proxy, or governance document. The document is an event-driven update about clinical trial results, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like earnings release or management report. The document length (7107 characters) and content confirm it is a standalone announcement rather than a full report or presentation.
2026-04-27 English
ARS - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Annual Report
2026-04-24 English
8-K/A - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
M&A Activity Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It amends a previously filed 8-K to include historical financial statements of an acquired company (Bluejay Therapeutics) and pro forma financial information related to the acquisition and PIPE financing. The document includes detailed financial exhibits and pro forma financial data, which are typical for merger-related disclosures. The primary purpose is to update and supplement the original 8-K with required financial information about the acquisition. This type of filing is best classified under M&A Activity (TAR) because it relates to merger announcements and associated financial disclosures. It is not a full annual report, audit report, or earnings release, but a regulatory filing specific to merger activity and related financial information.
2026-04-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.